GLP-1 Medication Persistence, a Key Component of Weight Loss
Medication persistence, or remaining on a medication as prescribed, is crucial for meaningful obesity management outcomes.
Medication persistence (remaining on a medication for the prescribed length of time) may be one of the greatest barriers to achieving clinically-meaningful outcomes in obesity management. Despite new medications showing weight loss results that rival bariatric surgery after one year of consistent use, most patients stop taking the prescribed medication too soon. Why is that?
Here, the Omada Insights Lab analyzed engagement, medication persistence, and weight loss results for members in the Enhanced GLP-1 Care Track through 24 weeks in the program. These findings indicate that:
-
Members in Omada’s Enhanced GLP-1 Care Track showed higher average medication persistence rates through 24 weeks compared to other real-world evidence
-
Those who persisted saw an average of 11% weight loss with semaglutide and 13% with tirzepatide, outcomes similar to what has been shown in clinical trials
-
Providing the right kind of support to enable people to persist with their GLP-1 medication use long enough to see benefits can help them achieve clinical trial-level weight loss, setting the stage for cardiometabolic disease risk reduction